The role of molecular imaging in the comprehensive examination of HIV-patients with ischemic heart disease

Cardiovascular disease is one of the most frequent cause of death globally. The greatest part is occupied by ischemic heart disease. HIV patients are composed to a higher risk of coronary heart disease.

The purpose of this work is to evaluate the possibility of using molecular imaging methods in a comprehensive examination of patients with HIV infection and ischemic heart disease.

Materials and methods. The survey group includes 32 patients with HIV infection. The comparison group consists of 25 age-matched patients with coronary heart disease and without HIV Infection. All patients were underwent myocardial perfusion scintigraphy using single photon emission computed tomography. Positron emission tomography with FDG were performed if necessary to assess the viability of the myocardium. The patients of the main group undergo diagnostic coronary angiography and standard set of laboratory and institutional diagnostic methods.

Results. The results of which confirm the high efficiency of radionuclide diagnostic methods for detecting perfusion disorders, contractility and myocardial viability in patients with HIV infection even at an early stage. They can be recommended for using in a comprehensive examination of patients with HIV infection.

1. Khan M.A., Hashim M.J., Mustafa H., et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020; 12 (7): e9349. https://doi.org/10.7759/cureus.9349

2. Barbarash O.L., Karpov Yu.A., Kashtalap V.V., et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020; 25 (11): 201–250. https://doi.org/10.15829/1560-4071-2020-4076 (In Russian)

3. Guide to cardiology. In 4 vol. / Ed. E.I. Chazov. Moscow: Practice, 2014. (In Russian)

4. Karpov Yu.A., Sorokin E.V. Stable coronary heart disease: strategy and tactics of treatment. Ed. 2nd, revised. and add.; Moscow: Medical Information Agency, 2012. 271 p. (In Russian)

5. Karpov Yu.A., Kukharchuk V.V., Lupanov V.P. et al. Diagnosis and treatment of chronic ischemic heart disease. Clinical guidelines. Russian Cardiology Bulletin. 2015; 10 (3): 3–33. (In Russian)

6. Cardiology: a national guide / Ed. E.V. Shlyakhto. Ed. 2nd, revised. and add. M.: GEOTAR-Media. 2015. 800 p. (In Russian)

7. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019; 6 (12): e831–e859. https://doi.org/10.1016/S2352-3018(19)30196-1

8. Triant V.A., Grinspoon S.K. Epidemiology of Ischemic Heart Disease in HIV. Curr. Opin. HIV AIDS. 2017; 12 (6): 540–547. https://doi.org/10.1097/COH.0000000000000410

9. Seecheran V.K., Giddings S.L., Seecheran N.A. Acute coronary syndromes in patients with HIV. Coron. Artery Dis. 2017; 28 (2): 166–172. https://doi.org/10.1097/MCA.0000000000000450

10. Anand A.R., Rachel G., Parthasarathy D. HIV Proteins and Endothelial Dysfunction: Implications in Cardiovascular Disease. Front. Cardiovasc. Med. 2018; 5: 185. https://doi.org/10.3389/fcvm.2018.00185

11. Ma G.S., Cotter B.R. HIV and cardiovascular disease: Much ado about nothing? Eur. Heart J. 2018; 39 (23): 2155–2157. https://doi.org/10.1093/eurheartj/ehy248

12. Nelson M.D., Szczepaniak L.S., LaBounty T.M. et al. Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. JACC: Cardiovasc. Imaging. 2014; 7 (11): 1175–1177. https://doi.org/10.1016/j.jcmg.2014.04.024

13. Neumann F.-J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019; 40 (2): 87–165. https://doi.org/10.1093/eurheartj/ehy394

14. Fihn S.D., Blankenship J.C., Alexander K.P. et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2014; 64 (18): 1929–1949. https://doi.org/10.1016/j.jacc.2014.07.017

15. Räber L., Mintz G.S., Koskinas K.C. et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur. Heart J. 2018; 39 (35): 3281–3300. https://doi.org/10.1093/eurheartj/ehy285

16. Johnson T.W., Räber L., di Mario C. et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur. Heart J. 2019; 40 (31): 2566–2584. https://doi.org/10.1093/eurheartj/ehz332

17. Rosen B.D., Fernandes V., McClelland R.L. et al. Relationship between baseline coronary calcium score and demonstration of coronary artery stenoses during follow-up MESA (Multi-Ethnic Study of Atherosclerosis). JACC Cardiovasc. Imaging. 2009; 2 (10): 1175–1183. https://doi.org/10.1016/j.jcmg.2009.06.014

18. Yan A.T., Shayne A.J., Brown K.A. et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006; 114 (1): 32–39. https://doi.org/10.1161/CIRCULATIONAHA.106.613414

19. Аншелес А.А., Сергиенко В.Б. Ядерная кардиология. М.: НМИЦ кардиологии, 2021. 516 с. Ansheles A.A., Sergienko V.B. Nuclear Cardiology. Moscow: NMIC Cardiology, 2021. 516 p. (In Russian)

20. Ansheles A.A., Khalikova E.I., Ryzhikova O.A. New method of quantifying myocardial perfusion impairments assessed with single-photon emission computed tomography. Medical Physics. 2016; 1 (69): 46–53. (In Russian)

21. Caobelli F., Kamani C.H., Nkoulou R., Buechel R. The importance of 18F-FDG cardiac PET/CT for the assessment of myocardial viability in ischaemic heart disease. Swiss Med. Wkly. 2021; 151 (21–22): w20511. https://doi.org/10.4414/smw.2021.20511

22. Gavrilova N.E., Metelskaya V.A., Perova N.V., Yarovaya E.B., Boytsov S.A., Mazaev V.P. Selection for the quantitative evaluation method of coronary arteries based upon comparative analysis of angiographic scales. Russian Journal of Cardiology. 2014; 110 (6): 24–29. https://doi.org/10.15829/1560-4071-2014-4-108-112 (In Russian)

23. Duncan A.D., Goff L.M., Peters B.S. Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study. PloS One. 2018; 13 (3): e0194199. https://doi.org/10.1371/journal.pone.0194199

24. Sarkar S., Brown T.T. Diabetes in People with HIV. Curr. Diab. Rep. 2021; 21 (5): 13. https://doi.org/10.1007/s11892-021-01382-8

25. Mariano-Goulart D., Jacquet J.M., Molinari N. et al. Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT? Eur. J. Nucl. Med. Mol. Imaging. 2013; 40 (2): 271–279. https://doi.org/10.1007/s00259-012-2262-1

26. Kristoffersen U.S., Lebech A.M., Wiinberg N. et al. Silent Ischemic Heart Disease and Pericardial Fat Volume in HIV-Infected Patients: A Case-Control Myocardial Perfusion Scintigraphy Study. PloS One. 2013; 8 (8): e72066. https://doi.org/10.1371/journal.pone.0072066